Active substances
Glubionate + Lactobionate
- SFDA 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| CALSYR SYRUP | 0.287,0.295 g,g | Syrup · Oral use | 1 Bottle | SAR 7.10 | NCE · OTC | KUWAIT SAUDI PHARMACEUTICAL INDUSTRIES | Valid |
Indications — CHI Daman Drug Formulary
BARIATRIC SURGERY; BREAST CANCER EARLY HORMONAL-SUPPORTIVE CARE; BREAST CANCER MET. HORMONAL-SUPPORTIVE CARE; HYPERPARATHYRODISM; JUVENILE IDIOPATHIC ARTHRITIS (JIA); MATERNAL AND CHILD HEALTHCARE- SUPPLEMENTATION FOR MOTHER AND CHILD; MYASTHENIA GRAVIS; OSTEOPOROSIS; POMPE DISEASE (LOPD); PSORIATIC ARTHRITIS; RENAL AND URETERIC STONES; RHEUMATOID ARITHRITIS-SUPPORTIVE CARE AND ADRS MANAGEMENT; SPINAL MUSCULAR ATROPHY - MAINTENANCE OF BONE HEALTH; VITAMIN D DEFICIENCY
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.